Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 9.24
CEMP's Cash to Debt is ranked lower than
56% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 36.54 vs. CEMP: 9.24 )
Ranked among companies with meaningful Cash to Debt only.
CEMP' s Cash to Debt Range Over the Past 10 Years
Min: 1.12  Med: 7.60 Max: No Debt
Current: 9.24
Equity to Asset 0.74
CEMP's Equity to Asset is ranked higher than
57% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CEMP: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
CEMP' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.72 Max: 0.82
Current: 0.74
0.48
0.82
F-Score: 4
Z-Score: 6.31
M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -351.53
CEMP's Operating margin (%) is ranked lower than
67% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: -72.13 vs. CEMP: -351.53 )
Ranked among companies with meaningful Operating margin (%) only.
CEMP' s Operating margin (%) Range Over the Past 10 Years
Min: -549.34  Med: -469.86 Max: -390.38
Current: -351.53
-549.34
-390.38
Net-margin (%) -362.12
CEMP's Net-margin (%) is ranked lower than
68% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. CEMP: -362.12 )
Ranked among companies with meaningful Net-margin (%) only.
CEMP' s Net-margin (%) Range Over the Past 10 Years
Min: -576.41  Med: -490.79 Max: -405.16
Current: -362.12
-576.41
-405.16
ROE (%) -74.33
CEMP's ROE (%) is ranked lower than
74% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -30.40 vs. CEMP: -74.33 )
Ranked among companies with meaningful ROE (%) only.
CEMP' s ROE (%) Range Over the Past 10 Years
Min: -94.12  Med: -82.32 Max: -70.51
Current: -74.33
-94.12
-70.51
ROA (%) -53.72
CEMP's ROA (%) is ranked lower than
71% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -26.44 vs. CEMP: -53.72 )
Ranked among companies with meaningful ROA (%) only.
CEMP' s ROA (%) Range Over the Past 10 Years
Min: -191.64  Med: -60.35 Max: -53.06
Current: -53.72
-191.64
-53.06
ROC (Joel Greenblatt) (%) -7803.50
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
84% of the 869 Companies
in the Global Biotechnology industry.

( Industry Median: -389.41 vs. CEMP: -7803.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -47405.52  Med: -36528.00 Max: -18139.82
Current: -7803.5
-47405.52
-18139.82
EBITDA Growth (3Y)(%) -64.50
CEMP's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 438 Companies
in the Global Biotechnology industry.

( Industry Median: -3.00 vs. CEMP: -64.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CEMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -67.6  Med: -65.90 Max: -64.5
Current: -64.5
-67.6
-64.5
EPS Growth (3Y)(%) -66.40
CEMP's EPS Growth (3Y)(%) is ranked lower than
98% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CEMP: -66.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CEMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.3  Med: -68.00 Max: -66.4
Current: -66.4
-69.3
-66.4
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CEMP Guru Trades in

Q1 2015

CEMP Guru Trades in Q1 2015

Paul Tudor Jones 15,611 sh (New)
» More
Q2 2015

CEMP Guru Trades in Q2 2015

Paul Tudor Jones 10,977 sh (-29.68%)
» More
Q3 2015

CEMP Guru Trades in Q3 2015

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.31
CEMP's P/B is ranked lower than
71% of the 795 Companies
in the Global Biotechnology industry.

( Industry Median: 2.92 vs. CEMP: 5.31 )
Ranked among companies with meaningful P/B only.
CEMP' s P/B Range Over the Past 10 Years
Min: 2.35  Med: 8.06 Max: 20.32
Current: 5.31
2.35
20.32
P/S 28.55
CEMP's P/S is ranked lower than
75% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: 8.94 vs. CEMP: 28.55 )
Ranked among companies with meaningful P/S only.
CEMP' s P/S Range Over the Past 10 Years
Min: 22.04  Med: 46.50 Max: 73.6
Current: 28.55
22.04
73.6
Current Ratio 8.83
CEMP's Current Ratio is ranked higher than
70% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. CEMP: 8.83 )
Ranked among companies with meaningful Current Ratio only.
CEMP' s Current Ratio Range Over the Past 10 Years
Min: 2.48  Med: 9.54 Max: 30.34
Current: 8.83
2.48
30.34
Quick Ratio 8.83
CEMP's Quick Ratio is ranked higher than
71% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.52 vs. CEMP: 8.83 )
Ranked among companies with meaningful Quick Ratio only.
CEMP' s Quick Ratio Range Over the Past 10 Years
Min: 2.48  Med: 9.54 Max: 30.34
Current: 8.83
2.48
30.34
Days Sales Outstanding 47.15
CEMP's Days Sales Outstanding is ranked higher than
67% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 62.48 vs. CEMP: 47.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.37  Med: 66.17 Max: 75.96
Current: 47.15
56.37
75.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.48
CEMP's Price/Net Cash is ranked lower than
55% of the 475 Companies
in the Global Biotechnology industry.

( Industry Median: 4.87 vs. CEMP: 5.48 )
Ranked among companies with meaningful Price/Net Cash only.
CEMP' s Price/Net Cash Range Over the Past 10 Years
Min: 2.64  Med: 6.10 Max: 16.1
Current: 5.48
2.64
16.1
Price/Net Current Asset Value 5.31
CEMP's Price/Net Current Asset Value is ranked lower than
55% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 4.65 vs. CEMP: 5.31 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.62  Med: 5.93 Max: 14.51
Current: 5.31
2.62
14.51
Price/Tangible Book 5.31
CEMP's Price/Tangible Book is ranked lower than
63% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CEMP: 5.31 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMP' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.61  Med: 5.87 Max: 14.42
Current: 5.31
2.61
14.42
Price/Median PS Value 0.60
CEMP's Price/Median PS Value is ranked higher than
68% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 0.86 vs. CEMP: 0.60 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 0.97 Max: 1.16
Current: 0.6
0.53
1.16
Earnings Yield (Greenblatt) (%) -16.50
CEMP's Earnings Yield (Greenblatt) (%) is ranked lower than
65% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -7.80 vs. CEMP: -16.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -15.14  Med: 0.00 Max: 0
Current: -16.5
-15.14
0

More Statistics

Revenue(Mil) $24
EPS $ -2.08
Beta1.63
Short Percentage of Float22.92%
52-Week Range $15.43 - 46.99
Shares Outstanding(Mil)43.97

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 24 13 55 113
EPS($) -2.13 -2.08 -1.70 -0.80
EPS without NRI($) -2.13 -2.08 -1.70 -0.80

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9C1.Germany,
Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
Cempra Reports Positive Data on Antibiotic Solithromycin Feb 09 2016
The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra’s Oral... Feb 05 2016
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Feb 04 2016
Cempra to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 03 2016
Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for... Feb 01 2016
[video]Spreading Zika Virus Is a Cause for Alarm, Says Cempra CEO Jan 28 2016
Cempra, Inc. (Nasdaq: CEMP) to Ring the Nasdaq Stock Market Closing Bell Jan 27 2016
Cempra, Inc. (Nasdaq: CEMP) to Ring the Nasdaq Stock Market Closing Bell Jan 27 2016
Cempra to Ring NASDAQ Closing Bell to Mark 10th Anniversary Jan 26 2016
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 21 2016
Cempra Completes Public Offering of Common Stock Jan 12 2016
Cempra Slumps: CEMP Falls 10.5% in Session Jan 08 2016
Chapel Hill drug developer Cempra slashes public offering by $93M Jan 07 2016
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Jan 07 2016
Cempra Prices Public Offering of Common Stock Jan 06 2016
Cempra to Present at J.P. Morgan Healthcare Conference Jan 06 2016
​Chapel Hill drug developer Cempra looks to raise $200M Jan 05 2016
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2016
Cempra Announces Proposed Public Offering of $175 Million of Common Stock Jan 05 2016
Cempra, Inc. breached its 50 day moving average in a Bearish Manner : January 5, 2016 Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK